Xeris Biopharma Holdings, Inc.
0A8E.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.81B
Close$
Share Statistics
| Market cap | $1.81 Billion |
|---|---|
| Enterprise Value | $1.98 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.85 |
| Outstanding Shares | 172,823,455 |
Return
| Return on Equity | 176.34% |
|---|---|
| Return on Assets | -4.17% |
| Return on Invested Capital | 0.71% |
Valuation & Multiples
| P/E Ratio | -107.93 |
|---|---|
| PEG | -7.13 |
| Price to Sales | 10.0 |
| Price to Book Ratio | -10.0 |
| Enterprise Value to Revenue | 5.89 |
| Enterprise Value to EBIT | 1256.02 |
| Enterprise Value to Net Income | -116 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -29.74 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$90.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$101.68 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Xeris Pharmaceuticals Inc
435 employees
CEO: paul Edick Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering, developing, and commercializing medical treatments for individuals suffering from conditions in endocrinology, neurology, and ...